Related Experiment Video
Updated: Aug 13, 2026
Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
Published on: March 25, 2019
Human ovarian cancers specifically bind daunorubicin-OC-125 conjugate: an immunofluorescence study
1Department of Pathology, University Medical School of Debrecen, Hungary.
Abstract:
This study was designed to test the specific binding to human ovarian serous adenocarcinomas of a drug-antibody conjugate [daunorubicin (DNR-OC-125], made from a new analog (PIPP-DNR) of daunorubicin that chemically links the drug to monoclonal antibodies. We recently reported that the DNR-OC-125 conjugate is selectively toxic in vitro to dividing cell populations of the human ovarian cancer cell lines SK-OV-3 and OVCAR-3 that express the CA-125 antigen [F. Sweet, L. O. Rosik, G. M. Sommers, and J. L. Collins, Gynecol. Oncol. 34, 305-311 (1989)]. In the present study, immunofluorescence data show that the DNR-OC-125 conjugate has high affinity and specificity for proliferating malignant cells from human ovarian tumors. The results demonstrate that the DNR-OC-125 conjugate retains the specific binding to CA-125 antigenic sites characteristic of the OC-125 monoclonal antibody moiety. The DNR-OC-125 conjugate selectively binds to CA-125 antigen-positive ovarian cancerous tissue in both cryostat and paraffin-embedded tissue sections. This is consistent with the earlier in vitro data from dividing populations of two human ovarian cancer cell lines that revealed retention by the DNR-OC-125 conjugate of both the specificity due to OC-125 and the cytotoxicity of daunorubicin. The present immunofluorescence studies in the DNR-OC-125 conjugate is tested on human ovarian serous tumors indicate that the OC-125 monoclonal antibody can indeed serve as a cancer-targeting carrier for daunorubicin and its analogs.
Insights
The daunorubicin-OC-125 drug-antibody conjugate specifically targets human ovarian cancer cells expressing the CA-125 antigen. This conjugate shows promise as a targeted delivery system for ovarian cancer therapy.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- The CA-125 antigen is a biomarker often overexpressed in human ovarian cancers.
- Drug-antibody conjugates offer a strategy for targeted cancer therapy by delivering cytotoxic agents directly to tumor cells.
- Previous in vitro studies demonstrated the selective toxicity of daunorubicin-OC-125 (DNR-OC-125) against ovarian cancer cell lines expressing CA-125.
Purpose of the Study:
- To evaluate the in vivo binding specificity and affinity of the daunorubicin-OC-125 (DNR-OC-125) drug-antibody conjugate to human ovarian serous adenocarcinomas.
- To confirm the retention of CA-125 antigen binding by the OC-125 monoclonal antibody component of the conjugate.
- To assess the potential of the OC-125 monoclonal antibody as a targeting carrier for daunorubicin analogs in ovarian cancer.
Main Methods:
- Immunofluorescence was employed to assess the binding of the DNR-OC-125 conjugate to human ovarian tumor tissues.
- The study utilized both cryostat and paraffin-embedded tissue sections to evaluate conjugate binding.
- Binding specificity was confirmed by examining the interaction with CA-125 antigen-positive ovarian cancerous tissue.
Main Results:
- Immunofluorescence data confirmed high affinity and specificity of the DNR-OC-125 conjugate for proliferating malignant cells in human ovarian tumors.
- The DNR-OC-125 conjugate demonstrated specific binding to CA-125 antigenic sites, consistent with the OC-125 monoclonal antibody's known binding characteristics.
- Selective binding of the conjugate to CA-125 antigen-positive ovarian cancerous tissue was observed in various tissue preparations.
Conclusions:
- The OC-125 monoclonal antibody retains its specific binding to CA-125 antigens when conjugated with daunorubicin (DNR-OC-125).
- The DNR-OC-125 conjugate exhibits selective binding to human ovarian serous adenocarcinomas expressing the CA-125 antigen.
- These findings support the potential of the OC-125 monoclonal antibody as an effective cancer-targeting carrier for daunorubicin and its analogs in ovarian cancer treatment.
